Corcept Therapeutics (CORT) said Thursday the phase 2 trial of its experimental therapy, dazucorilant, did not meet its primary endpoint, sending shares down 1.4% in premarket activity.
Dazucorilant is intended to treat amyotrophic lateral sclerosis, a fatal motor neuron disease.
The company said the study showed that therapy did not meet its primary endpoint of improved outcome in the ALS functional rating scale-revised in patients who received dazucorilant compared to patients who received placebo.
However, no deaths occurred in the patient group receiving 300 mg of dazucorilant compared to five deaths in the placebo group, the company said, adding that an exploratory one-year analysis also demonstrated continued survival benefit, especially for those who stayed on 300 mg for over 24 weeks.
The long-term extension study is still ongoing, the company added.
Price: 68.99, Change: -0.99, Percent Change: -1.41
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。